Tetra Bio-Pharma completes safety report, launches clinical trial

Tetra Bio-Pharma Inc. (CSE: C.TBP, OTCQB: GRPOF, Forum) said Wednesday it has submitted a report on the safety and pharmacokinetics of PPP001 (smokeable marijuana) to Health Canada.

The company is also launching the preparation of a Phase 111 clinical trial in collaboration with Quebec’s leading medical cannabis clinic, Santé Cannabis.

More information can be found here.

Tetra-Bio Pharma is a multi-subsidiary publicly traded company engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

The Ontario-based company was in the news recently when it and and Aphria Inc. (TSX: V.APH, OTCQB: APHQF, Forum) announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.

Tetra and Aphria will enter into a joint supply agreement, the companies said in a press release.

Full Disclosure: Tetra Bio-Pharma Inc.  is a paid client of Stockhouse Publishing.

... read more at: http://www.stockhouse.com/news/newswire/2017/06/07/tetra-bio-pharma-completes-safety-report-launches-clinical-trial

Leave a Reply

Your email address will not be published. Required fields are marked *